Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 2 | EJNMMI Radiopharmacy and Chemistry

Fig. 2

From: Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer

Fig. 2

A SDS-PAGE analysis under non-reducing conditions of trastuzumab (lanes 1,4,7), BnDTPA-trastuzumab (lanes 2,5,8) and BnDTPA-trastuzumab-NLS in kit lots 17N014, 17N026 and 18N008 (lanes 3, 6, 9). B. SDS-PAGE analysis under reducing conditions (DTT) of trastuzumab (lanes 10,13,16), BnDTPA-trastuzumab (lanes 11,14,15) and BnDTPA-trastuzumab-NLS in kit lots 17N014, 17N026 and 18N008 (lanes 12, 15,18). The gel was stained with Coomassie R-250 Brilliant Blue. MW: broad range molecular weight standards

Back to article page